NCT06398587 2024-07-19
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
Clinical Trials
15 trialsNCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05514912 2023-12-26
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
Phase 2 Withdrawn
NCT05251038 2023-05-11
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT02067416 2023-02-02
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT04249167 2023-01-06
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Mayo Clinic
Phase EARLY_PHASE1 Withdrawn
NCT02117817 2022-07-28
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Rutgers, The State University of New Jersey
Phase 1 Withdrawn
NCT02662634 2022-03-18
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
GU Research Network, LLC
Phase 2 Withdrawn
NCT04134468 2020-01-31
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Withdrawn
NCT02300935 2019-05-30
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
SCRI Development Innovations, LLC
Phase 1 Withdrawn
NCT00820768 2018-04-11
A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Celgene
Phase 1 Withdrawn
NCT02405910 2017-11-06
Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.
West Virginia University
Phase 2 Withdrawn
NCT02718742 2016-04-18
Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer
Mayo Clinic
Phase 2 Withdrawn
NCT02048943 2015-01-09
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT01933061 2014-02-04
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
Celgene
Phase 2 Withdrawn